Why Generics?

At Mylan, we have one global quality standard in everything we do.

Because there is nothing generic about our standards. Our internal teams conduct reviews of all products, start to finish. No matter where in the world they are made.

Why such high standards? Because we truly care about the people who will be helped by the medicines we make. And we believe in earning that trust, from physicians, pharmacists, other health care professionals and patients, every day. It’s why we say, “Our Mylan, Is Your Mylan.”

Want to know more about generic medicines? See the facts, figures and bioequivalence requirements below.

Generic medicine accounted for 63% of the retail prescriptions filled in 2012. This equates to 353 million prescriptions!
Health Canada must approve every generic medicine before it can be sold in Canada.
To gain Health Canada approval, generic medicines must be proven to be “bioequivalent” to their brand name counterparts. That means generic and brand name medicines are equivalent in terms of strength, dosage, quality, safety and efficacy.
Generics cost an average of 60% less than their brand counterparts. The price of generic medicines is usually lower, when compared to brand name medicines, since generic medicines are not invented from scratch, generally not subject to clinical trials or supported by advertising campaigns.
In 2011, the use of lower cost generic prescription medicines saved Canadian governments, employers and consumers nearly $8.5 billion.
Main factors behind the growth of the generics industry
- Aging population
- Desire to reduce health care spending
The key to Mylan’s ability to bring new generics to market, especially medicines that are difficult-to-manufacture and difficult-to-formulate. Find out about our therapeutic innovation.